Altimmune, Inc. · NASDAQ:ALT

Altimmune — Technical Presentation (November 2026)

17 slides from Altimmune's technical presentation, Nov 9, 2026

  1. Slide 1: Efficacy and Safety of Pemvidutide in Adults with Alcohol Use Disorder: RECLAIM

    Efficacy and Safety of Pemvidutide in the Treatment of Adults with Alcohol Use Disorder: Results from RECLAIM, a 24-Week Phase 2 Randomized Double-Blind Placebo- Controlled Trial Henry R. Kranzler1, Shaheen Tomah2, W. Kyle Simmons3, Stephanie S. O’Malley4, Joseph P. Schacht5, Xiaoxi Li2, Christophe

  2. Slide 2: Disclosures

    Disclosures Dr. Kranzler’s Disclosures: Dr. Kranzler serves on advisory boards for Altimmune, Inc. and Clearmind Medicine; consults for Altimmune, Inc., Eli Lilly and Company, Sobrera Pharmaceuticals, Ribocure and Boehringer Ingelheim; and receives research support from Alkermes, Altimmune, and Eli

  3. Slide 3: Alcohol Use Disorder Causes Severe Clinical Complications with Substantial Gaps in Care

    INTRODUCTION Alcohol Use Disorder (AUD) Causes Severe Clinical Complications with Substantial Gaps in Current Care Epidemiological Burden Healthcare Burden Clinical Burden 57.9M Engage in binge ~2M Adult hospitalizations ~178,000 Deaths annually drinking monthly annually due to excessive alcohol use

  4. Slide 4: Pemvidutide is a Balanced 1:1 Glucagon/GLP-1 Dual Receptor Agonist

    INTRODUCTION Pemvidutide is a Balanced 1:1 Glucagon/GLP-1 Dual Receptor Agonist COOH Glucagon specificity EuPort Domain (CH2)n Provides direct liver effects, including liver Allows for weekly dosing and fat reduction, leading to reductions in may contribute to tolerabilitya inflammation and fibrosis

  5. Slide 5: RECLAIM Phase 2 AUD Trial Design

    METHODS RECLAIM Phase 2 AUD Trial Design A Phase 2, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of pemvidutide in AUD (NCT06987513) Week 24 Endpoints Week 0 Week 24 Primary endpoint Adult Patient Population 4 weeks 4 weeks 16 weeks • Heavy drink

  6. Slide 6: High Overall Retention (91%) with Similar Treatment Discontinuation Across Groups

    RESULTS High Overall Retention (91%) with Similar Treatment Discontinuation Across Groups 194 assessed for eligibility 94 screen failures 100 randomized Placebo (N=50) Pemvidutide 2.4 mg (N=50) 11 discontinued treatmenta 10 discontinued treatmentb 39 (78%) completed treatment 40 (80%) completed trea

  7. Slide 7: Demographic and Baseline Clinical Characteristics Similar Across Groups

    RESULTS Demographic and Baseline Clinical Characteristics Similar Across Groups Characteristic Placebo (N=50) Pemvidutide 2.4 mg (N=50) Age, years (SD) 50.0 (10.0) 50.8 (11.9) Female sex, n (%) 26 (52) 26 (52) Body weight, kg (SD) 96.0 (21.4) 92.0 (19.1) BMI, kg/m2 (SD) 32.5 (6.6) 32.3 (5.8) AUD by

  8. Slide 8: Significantly Greater Reduction in Heavy Drinking Days/Week than Placebo

    RESULTS Pemvidutide Achieved Significantly Greater Reduction in Heavy Drinking Days/Week than Placebo (Primary Endpoint) Heavy Drinking Days (HDDs)/Week 0 LSM Change from Baseline (HDD/Week ± SE) *P = 0.0014 • Pemvidutide met the trial’s primary endpoint at -1 week 24 (reduction in HDDs/week) -2 o T

  9. Slide 9: Maintained Reduction in HDDs/Week in Sensitivity Analysis

    RESULTS Pemvidutide Maintained Reduction in HDDs/Week (Primary Endpoint) in Sensitivity Analysis Sensitivity Analysisa for Heavy Drinking Days (HDDs)/Week 0 LSM Change from Baseline (HDD/week ± SE) P = 0.008 -1 • The treatment effect on the primary endpoint at week 24 (reduction in HDDs/week) remain

  10. Slide 10: Higher Rates of ≥2-level WHO-RDL Reduction and Zero HDDs

    RESULTS Pemvidutide Achieved Higher Rates of a ≥2-level WHO- RDL Reduction and Zero HDDs (FDA Registrational Endpoints) ≥2-level World Health Organization Zero Heavy Drinking Days Risk Drinking Level (WHO-RDL) 100% 100% *P = 0.0049 P = 0.0066 Percentage of Patients (%) 80% 80% Percentage of Patients

  11. Slide 11: Reduction in Serum PEth Levels

    RESULTS Pemvidutide Showed a Reduction in Serum PEth Levels (Sensitive and Specific Biomarker of Alcohol Consumption) Serum Phosphatidylethanol (PEth) 100 P <0.0001 LSM Change from Baseline (ng/mL ± SE) 22.0 50 0 • Self-reported drinking outcomes were corroborated by reductions in objective -50 PEth

  12. Slide 12: Increase in Percent Days Abstinent

    RESULTS Pemvidutide Showed an Increase in Percent Days Abstinent Percent Days Abstinent (PDA) Drinks Per Drinking Daya (DDD) LSM Change from Baseline (Average DDD ± SE) 50 0 LSM Change from Baseline (% of Days ± SE) P = 0.0075 38.9% P = 0.203 -1 40 -2 30 20.5% -3 -3.8 20 -4 10 -5 Placebo (n=50) Plac

  13. Slide 13: Progressive Decrease in Body Weight and Reduced FIB-4 Scores

    RESULTS Pemvidutide Showed Progressive Decrease in Body Weight and Reduced FIB-4 Scores Change in FIB-4 Score At Week 24 Among Percent Change in Body Weight Patients with Baseline FIB-4 ≥1.3a (n=25) 2 P <0.0001 P = 0.0301 LSM Percent Change from Baseline (% ± SE) 0.4% 0.4 0.2 LSM Change from Baselin

  14. Slide 14: Adverse Events Were Predominantly Mild or Moderate

    RESULTS Adverse Events Were Predominantly Mild or Moderate Event, n (%) Placebo (N=50) Pemvidutide 2.4 mg (N=50) Serious adverse events 1 (2.0)a 2 (4.0)b Serious adverse events related to trial drug 0 (0.0) 1 (2.0) Severe adverse events 3 (6.0) 6 (12.0) Severe adverse events related to trial drug 0

  15. Slide 15: Summary and Future Directions

    Summary ▪ The RECLAIM trial met its primary endpoint, with pemvidutide demonstrating a significantly greater reduction in HDDs/week than placebo among patients with moderate-to-severe AUD ▪ Patients treated with pemvidutide showed consistent improvements in other measures of self- reported alcohol c

  16. Slide 16: Acknowledgements

    Acknowledgements • This study was funded by Altimmune, Inc. • Patients & Clinical Trial Team o Patients for their important contributions to this trial o Clinical investigators and the Altimmune clinical trial team who contributed to the conduct of the trial • Medical Communications Support o Boston

  17. Slide 17: Thank you! Questions?

    Thank you! Questions? AASLD

Altimmune — Technical Presentation (November 2026) on 6ix